Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2563

1.

Elevated blood plasma levels of tissue factor-bearing extracellular vesicles in patients with atrial fibrillation.

Mørk M, Andreasen JJ, Rasmussen LH, Lip GYH, Pedersen S, Bæk R, Jørgensen MM, Kristensen SR.

Thromb Res. 2018 Dec 2;173:141-150. doi: 10.1016/j.thromres.2018.11.026. [Epub ahead of print]

PMID:
30530119
2.

Relation of the CHA2DS2-VASc Score to Risk of Thrombotic and Embolic Stroke in Community-Dwelling Individuals Without Atrial Fibrillation (From The Atherosclerosis Risk in Communities [ARIC] Study).

Koene RJ, Alraies MC, Norby FL, Soliman EZ, Maheshwari A, Lip GYH, Alonso A, Chen LY.

Am J Cardiol. 2018 Nov 6. pii: S0002-9149(18)32052-6. doi: 10.1016/j.amjcard.2018.10.037. [Epub ahead of print]

PMID:
30527796
3.

Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF).

Lip GYH, Merino JL, Banach M, de Groot JR, Maier LS, Themistoclakis S, Boriani G, Jin J, Melino M, Winters SM, Goette A.

Am J Cardiol. 2018 Nov 24. pii: S0002-9149(18)32100-3. doi: 10.1016/j.amjcard.2018.11.019. [Epub ahead of print]

PMID:
30527775
4.

[2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)].

Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I.

G Ital Cardiol (Rome). 2018 Nov;19(11):3-73. doi: 10.1714/3026.30245. Italian. No abstract available.

PMID:
30520455
5.

Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis).

Korjian S, Daaboul Y, Laliberté F, Zhao Q, Mehran R, Bode C, Halperin J, Verheugt FWA, Lip GYH, Cohen M, Peterson ED, Fox KAA, Gibson CM, Pinto DS; PIONEER AF-PCI Investigators.

Am J Cardiol. 2018 Nov 6. pii: S0002-9149(18)32048-4. doi: 10.1016/j.amjcard.2018.10.033. [Epub ahead of print]

PMID:
30502047
6.

Risk assessment and management of atrial fibrillation patients with left atrial thrombus.

Miyazawa K, Lip GYH.

Pacing Clin Electrophysiol. 2018 Nov 28. doi: 10.1111/pace.13556. [Epub ahead of print] No abstract available.

PMID:
30488453
7.

Frailty and multi-morbidities should not govern oral anticoagulation therapy prescribing for patients with atrial fibrillation.

Fawzy AM, Olshansky B, Lip GYH.

Am Heart J. 2018 Oct 31. pii: S0002-8703(18)30297-7. doi: 10.1016/j.ahj.2018.10.003. [Epub ahead of print] No abstract available.

PMID:
30487073
8.

Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Hypertrophic Cardiomyopathy: A Nationwide Cohort Study.

Jung H, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Pak HN, Lee MH, Joung B, Lip GYH.

Chest. 2018 Nov 22. pii: S0012-3692(18)32770-3. doi: 10.1016/j.chest.2018.11.009. [Epub ahead of print]

PMID:
30472021
9.

Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: multicentre cohort study.

Wilson D, Ambler G, Banerjee G, Shakeshaft C, Cohen H, Yousry TA, Al-Shahi Salman R, Lip GYH, Houlden H, Brown MM, Muir KW, Jäger HR, Werring DJ; Clinical relevance of Microbleeds in Stroke (CROMIS-2) collaborators.

J Neurol Neurosurg Psychiatry. 2018 Nov 19. pii: jnnp-2018-318890. doi: 10.1136/jnnp-2018-318890. [Epub ahead of print]

10.

Should the Presence or Extent of Coronary Artery Disease be Quantified in the CHA2DS2-VASc Score in Atrial Fibrillation? A Report from the Western Denmark Heart Registry.

Steensig K, Olesen KKW, Thim T, Nielsen JC, Jensen SE, Jensen LO, Kristensen SD, Bøtker HE, Lip GYH, Maeng M.

Thromb Haemost. 2018 Dec;118(12):2162-2170. doi: 10.1055/s-0038-1675401. Epub 2018 Nov 12.

PMID:
30419601
11.

The Importance and Future of Population Screening for Atrial Fibrillation.

Shin SY, Lip GYH.

Can J Cardiol. 2018 Nov;34(11):1407-1411. doi: 10.1016/j.cjca.2018.08.016. Epub 2018 Aug 17. Review.

PMID:
30404746
12.

The prothrombotic state in atrial fibrillation: pathophysiological and management implications.

Khan AA, Lip GYH.

Cardiovasc Res. 2018 Nov 2. doi: 10.1093/cvr/cvy272. [Epub ahead of print]

PMID:
30388199
13.

Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality.

Malavasi VL, Fantecchi E, Gianolio L, Pesce F, Longo G, Marietta M, Cascinu S, Lip GYH, Boriani G.

Eur J Intern Med. 2018 Oct 29. pii: S0953-6205(18)30405-9. doi: 10.1016/j.ejim.2018.10.012. [Epub ahead of print]

PMID:
30385084
14.

Stroke Risk Stratification for Atrial Fibrillation Patients With Hypertrophic Cardiomyopathy.

Jung H, Sung JH, Yang PS, Jang E, Yu HT, Kim TH, Pak HN, Lee MH, Joung B, Lip GYH.

J Am Coll Cardiol. 2018 Nov 6;72(19):2409-2411. doi: 10.1016/j.jacc.2018.07.098. No abstract available.

PMID:
30384898
15.

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.

Tepper PG, Mardekian J, Masseria C, Phatak H, Kamble S, Abdulsattar Y, Petkun W, Lip GYH.

PLoS One. 2018 Nov 1;13(11):e0205989. doi: 10.1371/journal.pone.0205989. eCollection 2018.

16.

Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation - The Fushimi AF Registry.

Masunaga N, Abe M, Ogawa H, Aono Y, Ikeda S, Doi K, An Y, Ishii M, Iguchi M, Esato M, Tsuji H, Wada H, Hasegawa K, Lip GYH, Akao M; Fushimi AF Registry Investigators.

Circ J. 2018 Nov 24;82(12):2983-2991. doi: 10.1253/circj.CJ-18-0872. Epub 2018 Oct 31.

17.

2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC).

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement D, Coca A, De Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen S, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder R, Shlyakhto E, Tsioufis K, Aboyans V, Desormais I.

Blood Press. 2018 Dec;27(6):314-340. doi: 10.1080/08037051.2018.1527177.

PMID:
30380928
18.

2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement D, Coca A, De Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen S, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder R, Shlyakhto E, Tsioufis K, Aboyans V, Desormais I; List of authors/Task Force members:.

J Hypertens. 2018 Dec;36(12):2284-2309. doi: 10.1097/HJH.0000000000001961. No abstract available.

PMID:
30379783
19.

Female Sex as a Risk Factor for Ischemic Stroke and Systemic Embolism in Chinese Patients With Atrial Fibrillation: A Report From the China-AF Study.

Lan DH, Jiang C, Du X, He L, Guo XY, Zuo S, Xia SJ, Chang SS, Wen SN, Wu JH, Ruan YF, Long DY, Tang RB, Yu RH, Sang CH, Bai R, Liu N, Jiang CX, Li SN, Dong JZ, Lip GYH, Chen AH, Ma CS.

J Am Heart Assoc. 2018 Oct 2;7(19):e009391. doi: 10.1161/JAHA.118.009391.

20.

Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS-BLED and GARFIELD-AF Bleeding Scores.

Proietti M, Rivera-Caravaca JM, Esteve-Pastor MA, Romiti GF, Marin F, Lip GYH.

J Am Heart Assoc. 2018 Sep 18;7(18):e009766. doi: 10.1161/JAHA.118.009766.

Supplemental Content

Support Center